Use this URL to cite or link to this record in EThOS: http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.492439
Title: Thiothymidine combined with UVA and raltitrexed as a potential novel therapy for bladder cancer
Author: Pridgeon, Simon W.
ISNI:       0000 0001 3501 4187
Awarding Body: University of Newcastle
Current Institution: University of Newcastle upon Tyne
Date of Award: 2009
Availability of Full Text:
Access from EThOS:
Abstract:
4-Thiothymidine closely resembles thymidine but has distinct photochemical properties. The molecule absorbs light in the UVA range and readily undergoes photochemical reactions. Thiothymidine can be incorporated into the DNA of replicating cells and subsequent exposure to UVA light results in the formation of lethal DNA adducts. This project aims to investigate whether the combination of thiothymidine and UVA may offer a selective treatment for bladder cancer. The rhymidylate synthetase inhibitor, raltitrexed, is hypothesised to increase thiothymidine incorporation into cellular DNA thus potentiating the efficacy of this treatment.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.492439  DOI: Not available
Share: